Results 31 to 40 of about 2,428,275 (198)

Intrinsic structural disorder confers cellular viability on oncogenic fusion proteins. [PDF]

PLoS Computational Biology, 2009
Chromosomal translocations, which often generate chimeric proteins by fusing segments of two distinct genes, represent the single major genetic aberration leading to cancer.
Hedi Hegyi, László Buday, Peter Tompa
doaj   +1 more source

Flow Cytometric Detection of BCR-ABL Fusion Proteins in Leukemia Patients Via An Immunobead Assay [PDF]

Blood, 2008
Abstract The BCR-ABL fusion gene results from the translocation t(9;22). It is the hallmark of chronic myeloid leukemia (CML) and is present in a poor-risk subgroup of precursor B cell acute lymphoblastic leukemia (ALL), which represents 25–30% of adult ALL and 3–5% of childhood ALL.
Jacques JM van Dongen, Frank J.T. Staal, Elizabeth Macintyre, Tomas Kalina, Lukasz Sedek, Paulo Lucio, Juan Flores Montero, Elisabeth R. Van Wering, Nancy Boeckx, Sebastian Böttcher, Vincent H.J. Van der Velden, E. Dekking, Floor Weerkamp   +12 more
openaire   +1 more source

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival [PDF]

, 2012
Recent evidence suggests CML stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated patients. We investigated whether CML stem cells, in a transgenic mouse model of CML-like disease or derived from ...
Allan, Elaine K., Mueller-Tidow, Carsten, Nicolini, Franck E., Bhatia, Ravi, Brunton, Valerie G, Myssina, Svetlana, Hamilton, Ashley, Mysina, Svetlana, Müller-Tidow, Carsten, Koschmieder, Steffen, Allan, Elaine K, Helgason, G. Vignir, Helgason, G Vignir, Brunton, Valerie G., Schemionek, Mirle, Zhang, Bin, Holyoake, Tessa L., Holyoake, Tessa L, Nicolini, Franck E   +18 more
core   +1 more source

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment? [PDF]

Reviews in Clinical Medicine, 2015
Chronic myelogenous leukemia is a myeloproliferative disorder presenting with anemia, elevated blood granulocytosis and the presence of immature granulocytes, basophilia, frequently thrombocytosis and spleen enlargement.
Hossein Rahimi, Zahra Mazloum Khorasani, Saeedeh Shariati   +2 more
doaj   +3 more sources

Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro. [PDF]

, 2011
The success of Imatinib (IM) therapy in chronic myeloid leukemia (CML) is compromised by the development of IM resistance and by a limited IM effect on hematopoietic stem cells.
Carsten Bokemeyer, Balabanov, S., Moll, J., Tessa L. Holyoake, Edgar Jost, Braig, Melanie, Stefan Balabanov, Moll, Jürgen, Rohe, Imke, Gontarewicz, A., Gunhild Keller, von Amsberg, Gunhild, Braig, M., Holyoake, Tessa L., Jost, E., Rohe, I., Jost, Edgar, Bosotti, Roberta, Tim H Brümmendorf, Bosotti, R., Balabanov, Stefan, Barett, Christine, Artur Gontarewicz, Holyoake, T.L., Laura Raddrizzani, Brümmendorf, T.H., Gontarewicz, Artur, Roberta Bosotti, Barett, C., Raddrizzani, Laura, Melanie Braig, Raddrizzani, L., Bokemeyer, C., Jürgen Moll, Tessa L Holyoake, Keller, G., Tim H. Brümmendorf, Bokemeyer, Carsten, Brümmendorf, Tim Henrik, Imke Rohe, Christine Barett   +40 more
core   +2 more sources

Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events

BMC Cancer, 2011
Background Leukemia is a heterogeneous disease commonly associated with recurrent chromosomal translocations that involve tyrosine kinases including BCR-ABL, TEL-PDGFRB and TEL-JAK2. Most studies on the activated tyrosine kinases have focused on proximal
Kim Hani, Gillis Lisa C, Jarvis Jordan D, Yang Stuart, Huang Kai, Der Sandy, Barber Dwayne L   +6 more
doaj   +1 more source

A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real time quantitative PCR [PDF]

, 2015
Serial quantification of BCR–ABL1 mRNA is an important therapeutic indicator in chronic myeloid leukaemia, but there is a substantial variation in results reported by different laboratories.
Mitterbauer, G., Kim, D.-W., S McCarron, Polakova, K.M., Hall, V, Preudhomme, C., K M Polakova, Hall, V., Schimmel, Heinz G., Cross, N.CP., L Foroni, Gerrard, G., Waits, Paula S., Cross, N.C.P., Jansson, Mattias,, Polakova, Km, Ozbek, U (Ugur), E O Leibundgut, El Housni, Hakim, R Ganderton, E Gineikienė, G Martinelli, Kizilors, A., White, H., Corbisier, P., Hayette, S, Colomer, D., Ganderton, R., Mueller, M. C., Kim, D-W, Van der Velden, V. H. J., de Lange, T, P Waits, Wilson, G., Mitterbauer Hohendanner, G, Cross, Nicholas C P., J Nomdedéu, Nagar, M, Nagar, M., Merle, P. A., Clench, T, Müller, M.C., Hochhaus, A., Fletcher, L, Deprez, Ludovic, Milner, B., Jurcek, Tomas, Nymoen, D. A., Andrikovics, H., T Sacha, Touloumenidou, Tasoula, Cayuela, J-M, Boeckx, N., Merle, Pauline A., Lange, T, Emons, H, Wang, L., Wang, L, D-W Kim, T Jurcek, Touloumenidou, T, Trapmann, Stefanie, A Aggerholm, Gineikiene, Eglė, Barbany, G., McCarron, S., V Kairisto, Mazoua, S., Schimmel, H, Polakova, K M, S Hayette, White, H, Barbany, G, H White, C Preudhomme, Cayuela, Jm, G Romeo, R Talmaci, Lin, Feng, K Zoi, Aggerholm, A, Lion, T, Akiki, S., Jurcek, T., Kairisto, V, A Kizilors, IZZO, BARBARA, Aggerholm, A., Van der Velden, Vh, Mueller, MC, F Lin, Colomer, D, Leibundgut, E O, Hochhaus, A, J Farrugia, Müller, Mc, Milner, B, G Mitterbauer-Hohendanner, Trapmann, S., Leibundgut, Eo, U Ozbek, Waits, P., Daraio, Filomena, Farrugia, J., Nomdedéu, J, Kizilors, Aytug, Preudhomme, C, Wilson, Gillian A., Ozbek, U, Lange, Thoralf, H Andrikovics, Andrikovics, H, El Housni, H, Emons, Hendrik, Deprez, L., Kim, Dong-Wook, Lin, F., Wilkinson, E., S Chudleigh, Dulucq, S., Schimmel, H., Izzo, B., D Colomer, Hayette, S., D Wren, Corbisier, Philippe, P Johnels, Cross, Nc, M Nagar, Zoi, K, V H J Van der Velden, N Boeckx, Bench, Anthony J., Aggerholm, Anni, El Housni, H., Gineikienė, E, H El Housni, Catherwood, M., Kairisto, Veli, Nagar, Meital, Catherwood, Mark Alexander, Hall, Victoria J., Wang, Lihui, Pfeifer, H, R Zadro, Milner, Benedict J., Nymoen, Dag André, Zadro, Renata, Leibundgut, E. O., Kim, Dw, S Trapmann, Fletcher, L., Kairisto, V., Daraio, F, Romeo, Giuliana, K Raudsepp, Akiki, S, Lin, F, L Wang, M Catherwood, Van der Velden, V.H.J., Dulucq, S, Wilson, G, M Jansson, Hochhaus, Andreas, Merle, P A, Nickless, Guillermina, Pajič, T, van der Velden, Vincent, Jansson, M, T Clench, Bench, A, Nomdedéu, Josep, T Touloumenidou, Universitat Autònoma de Barcelona. Departament de Medicina, Müller, M C, Deprez, L, Romeo, G, Foroni, L, Raudsepp, K, Mazoua, Stéphane, Wren, Dörte, Hayette, Sandrine, A Hochhaus, Machová Polakova, Katerina Machová, Foroni, L., Mitterbauer-Hohendanner, G, S Mazoua, Catherwood, M, Cayuela, J.M., Ziermann, Janine, F Daraio, S Dulucq, Sacha, T, Chudleigh, Sandra, G Gerrard, Chudleigh, S, G Wilson, Gerrard, Gareth, Farrugia, J, B Milner, M C Müller, P A Merle, Wilkinson, E, L Fletcher, Emons, H., Polakova, K. M., V Hall, Van der Velden, V.HJ., Wren, D., Nickless, G, Pajič, T., Sacha, T., Cross, N C P, Merle, Pa, Pfeifer, Heike, Merle, P.A., Ziermann, J, Touloumenidou, T., Zoi, K., Cross, NCP, Lion, Thomas, Trapmann, S, Wren, D, El Akiki, Susanna, McCarron, S, H Pfeifer, Corbisier, P, Wilkinson, Elizabeth, Pfeifer, H., Jurcek, T, Johnels, P., Boeckx, Nancy, Gerrard, G, N C P Cross, Ziermann, J., Leibundgut, O., Zadro, R., Martinelli, G., Colomer, Dolors, Izzo, B, White, Helen E., Romeo, G., T Pajič, Farrugia, Joanna, H Emons, P Corbisier, A Bench, Lange, T., G Barbany, Foroni, Letizia, Ganderton, Rosalind H., Raudsepp, K., Mitterbauer-Hohendanner, G., J Ziermann, Martinelli, G, Waits, P, Clench, Tim, Ganderton, R, Daraio, F., Zadro, R, H Schimmel, Kim, D-W., Johnels, Petra, Fletcher, Linda, G Nickless, D A Nymoen, Chudleigh, S., Talmaci, R., Mazoua, S, Nymoen, Da, Oppliger Leibundgut, Elisabeth, T Lion, Bench, A., Dulucq, Stéphanie, Clench, T., Nickless, G., Gineikienė, E., L Deprez, E Wilkinson, Zoi, Katerina, Boeckx, N, Nymoen, D.A., Leibundgut, E.O., T Lange, Nymoen, D A, J-M Cayuela, Mueller, M.C., Johnels, P, Barbany-Bustinza, Gisela, Sacha, Tomasz, Jansson, M., Mitterbauer-Hohendanner, Gerlinde Juliane, Lion, T., Müller, Martin Christian, Van der Velden, VHJ, Cayuela, J-M., B Izzo, Kizilors, A, Kim, D.W., Van der Velden, V H J, Van der Velden54, V.H.J., Cayuela, Jean Michel, Ozbek, U., MARTINELLI, GIOVANNI, Andrikovics, Hajnalka, Talmaci, R, Nomdedéu, J., Cross, N. C. P., S Akiki, Preudhomme, Claude, Ozbek, Ugur, Pajič, Tadej, Wang, L (Liang), Van Der Velden, Vincent H. J., Jansson, Mattias, Deprez, Liesbet   +316 more
core   +3 more sources

Detection of derivative 9 deletion by BCR-ABL fluorescence in-situ hybridization signal pattern to evaluate treatment response in CML patients [PDF]

Archive of Oncology, 2009
Background: To evaluate prognostic effect of submicroscopic deletions involving breakage and fusion points of the derivative chromosome 9 and 22 in chronic myeloid leukemia in untreated patients and their follow up samples to correlate with disease ...
Bakshi Sonal R., Shah Pankaj M., Shukla Shilin N., Dalal Esha N., Iyer Ramesh R., Brahmbhatt Manisha M., Gajjar Sarju B., Trivedi Pina J., Patel Beena P.   +8 more
doaj   +1 more source

The tyrosine phosphatase TC48 interacts with and inactivates the oncogenic fusion protein BCR-Abl but not cellular Abl

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2013
The chimeric oncoprotein BCR-Abl exhibits deregulated protein tyrosine kinase activity and is responsible for the pathogenesis of certain human leukemias, such as chronic myelogenous leukemia. The activities of cellular Abl (c-Abl) and BCR-Abl are stringently regulated and the cellular mechanisms involved in their inactivation are poorly understood ...
Mitra, Aninda, Sasikumar, Kotagiri, Parthasaradhi, B.V.V., Radha, Vegesna   +3 more
openaire   +2 more sources

The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines [PDF]

, 2009
Background Imatinib mesylate, a selective inhibitor of Abl tyrosine kinase, is efficacious in treating chronic myeloid leukaemia (CML) and Ph+ acute lymphoblastic leukaemia (ALL).
Schwarz, Kerstin, Ruthardt, Martin, Romanski Annette, Romanski, Annette, Ruthardt Martin, Ottmann, Oliver G., Ottmann, Oliver G, Bacic, Biserka, Gwanmesia Patricia, Gwanmesia, Patricia Mambou, Schwarz Kerstin, Ottmann Oliver G, Bacic Biserka   +12 more
core   +1 more source